News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Former Genzyme Corporation (GENZ) Subsidiary rEVO Biologics Files For $75 Million IPO


6/30/2014 7:11:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

rEVO Biologics, which markets a recombinant protein that prevents blood clots in patients with a rare disorder, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company was originally formed as a subsidiary of Genzyme and completed an IPO in 2002, before it was bought by French pharmaceutical company LFB Biotechnologies in 2010.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES